Glycerol-3-phosphate acyltransferase-1 upregulation by O-GlcNAcylation of Sp1 protects against hypoxia-induced mouse embryonic stem cell apoptosis via mTOR activation

HJ Lee¹, JM Ryu², YH Jung¹, KH Lee¹, DI Kim¹ and HJ Han*¹

Oxygen signaling is critical for stem cell regulation, and oxidative stress-induced stem cell apoptosis decreases the efficiency of stem cell therapy. Hypoxia activates O-linked β-N-acetyl glucosaminyltransferase (O-GlcNAc) of stem cells, which contributes to regulation of cellular metabolism, as well as cell fate. Our study investigated the role of O-GlcNAcylation via glucosamine in the protection of hypoxia-induced apoptosis of mouse embryonic stem cells (mESCs). Hypoxia increased mESCs apoptosis in a time-dependent manner. Moreover, hypoxia also slightly increased the O-GlcNAc level. Glucosamine treatment further enhanced the O-GlcNAc level and prevented hypoxia-induced mESC apoptosis, which was suppressed by O-GlcNAc transferase inhibitors. In addition, hypoxia regulated several lipid metabolic enzymes, whereas glucosamine increased expression of glycerol-3-phosphate acyltransferase-1 (GPAT1), a lipid metabolic enzyme producing lysophosphatidic acid (LPA). In addition, glucosamine-increased O-GlcNAcylation of Sp1, which subsequently leads to Sp1 nuclear translocation and GPAT1 expression. Silencing of GPAT1 by gpat1 siRNA transfection reduced glucosamine-mediated anti-apoptosis in mESCs and reduced mammalian target of rapamycin (mTOR) phosphorylation. Indeed, LPA prevented mESCs from undergoing hypoxia-induced apoptosis and increased phosphorylation of mTOR and its substrates (S6K1 and 4EBP1). Moreover, mTOR inactivation by rapamycin (mTOR inhibitor) increased pro-apoptotic proteins expressions and mESC apoptosis. Furthermore, transplantation of non-targeting siRNA and glucosamine-treated mESCs increased cell survival and inhibited flap necrosis in mouse skin flap model. Conversely, silencing of GPAT1 expression reversed those glucosamine effects. In conclusion, enhancing O-GlcNAcylation of Sp1 by glucosamine stimulates GPAT1 expression, which leads to inhibition of hypoxia-induced mESC apoptosis via mTOR activation.

Cell Death and Disease (2016) 7, e2158; doi:10.1038/cddis.2015.410; published online 24 March 2016

Stem cells in the body are exposed to low oxygen pressure owing to the physiological distribution of vessels.¹ This hypoxic niche for stem cells is essential to maintain the metabolic characteristics of stem cells.² Thus, describing the oxygen nature of this stem cell niche is important for elucidating stem cell regulation. Oxygen signaling is a major determinant of cell fate-controlling cellular processes. Control of oxygen signaling in stem cells has the potential to regulate embryonic development, cell cultivation, cell reprogramming, and transplantation in regenerative medicine.¹³⁻⁶ There are many reports showing the effects of hypoxia on various kinds of stem cells, and it has been shown that hypoxia has a paradoxical role in stem cell behaviors and cell fate regulation related to stem cell type, ageing, and oxygen concentration.⁵⁻⁷⁻⁹ Studies of mechanisms by which stem cells function under hypoxia, and how they are regulated, have been undertaken. Several investigators recently reported that hypoxia-mediated stem cell metabolic alteration is associated with stem cell function; as a result, interest in the intersection between hypoxia and stem cell metabolism is growing.¹⁰⁻¹¹ However, which metabolic factors are important for stem cell fate under hypoxia have not been elucidated.

O-linked β-N-acetyl glucosaminylation (O-GlcNAc) is affected by cellular nutrient status and extra-cellular stresses including hypoxia.¹²⁻¹⁴ A hypoxia-induced glycolytic switch primarily stimulates hexosamine biosynthetic pathway (HBP) flux, which induces O-GlcNAc signaling.¹⁵ O-GlcNAcylation is catalyzed by O-linked N-acetyl glucosamine transferase (OGT) to add N-acetyl glucosamine to the serine or threonine residues of proteins.¹⁶⁻¹⁸ O-GlcNAcylation acts as an essential factor for controlling physiological processes including migration, proliferation, and survival in stem cells,

¹Department of Veterinary Physiology, College of Veterinary Medicine, Research Institute for Veterinary Science and BK21 Creative Veterinary Research Center, Seoul National University, Seoul, Korea and ᵃDepartment of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Korea

*Corresponding author: HJ Han, Department of Veterinary Physiology, College of Veterinary Medicine, Research Institute for Veterinary Science, Seoul National University, 151-741 Seoul, Korea. Tel: +82 2 880 1261; Fax: +82 2 880 2732; E-mail: hjhan@snu.ac.kr

Abbreviations: ACC1, acetyl-coenzyme A carboxylase 1; BrdU, bromodeoxyuridine; CPT1, carnitine palmitoyltransferase; ESC, embryonic stem cell; FASN, fatty acid synthase; GlcN, glucosamine; GPAT1, glycerol-3-phosphate acyltransferase-1; HBP, hexosamine biosynthetic pathway; hMSCs, human mesenchymal stem cells; HRP, horseradish peroxidase; LPA, lysophosphatidic acid; LPAAT, lysophosphatidic acid acyltransferase; MAGL, monoacylglycerol lipase; mESC, mouse embryonic stem cell; mTOR, mammalian target of rapamycin; N.S, not statistically significant; NT, non-targeting; GlcNAc, O-linked β-N-acetyl glucosaminylation; GlcN, N-acetyl-D-glucosamine; OGT, O-linked N-acetyl glucosamine transferase; PI, propidium iodide; Ptx, pertussis toxin; PVDF, polyvinylidene fluoride; SCD1, stearoyl-CoA desaturase 1; siRNA, small interfering RNA; ROS, reactive oxygen species

Received 21.10.15; revised 10.12.15; accepted 14.12.15; Edited by S Lavandero
and recently it was considered as a potential strategy for use in stem cell therapy.\textsuperscript{19–21} In addition, as many human metabolic diseases such as diabetes and cancer are attributed to aberrant O-GlcNAcylation, unraveling HBP-mediated O-GlcNAc signaling is important in the development of practical strategies for metabolic diseases treatment. For example, Liu et al.\textsuperscript{22} showed that glucosamine-mediated O-GlcNAcylation induced resistance to tissue damage resulting from ischemic injury and provided cardio-protection in an animal model. Furthermore, O-GlcNAcylation interacts with other nutrient metabolic pathways such as lipogenesis, gluconeogenesis, and glycogen synthesis.\textsuperscript{12,23,24} Among these metabolic pathways, lipid metabolism is reported to have a central role in controlling stem cell fate.\textsuperscript{25,26} Collectively, these results suggest that O-GlcNAcylation can be a useful tool for use in cellular metabolic regulation, and identification of an O-GlcNAcylation-regulating potential lipid metabolic factor, which is important for stem cell regulation, may suggest potentially useful metabolic approach in stem cell therapy.

Embryonic stem cells (ESCs) are distinctive in that they have a self-renewal capacity, exhibit pluripotency to enable differentiation into cellular derivatives of three lineages, and may be used as a representative in vitro model in the study of early embryo development, pluripotent stem cell physiology, and clinical applications.\textsuperscript{27–29} Despite the clinical limitation associated with ESCs and the possibility of cancer formation, several studies into the therapeutic effects of ESCs in regenerative medicine have been reported. Indeed, administrations of human or mouse ESCs (mESCs) has induced a paracrine effect and improved damaged cell functions.\textsuperscript{30–32} However, despite the benefit of ESCs in regenerative medicine, ESC apoptosis remains an impediment to ESC applications using hypoxia.\textsuperscript{33–35} Thus, researchers are investigating ways to minimize ESC apoptosis and control ESC fate under hypoxia. In this study, we used glucosamine to induce O-GlcNAcylation. Therefore, our study investigated the role of O-GlcNAcylation via glucosamine (GlcN) which is recognized as a HBP activator\textsuperscript{36} in lipid metabolism and in protection of mESC apoptosis under hypoxia.

Results

Effect of O-GlcNAcylation on mESC survival under hypoxia. To determine the effect of hypoxia on glucosamine-induced metabolic enzyme expressions in mESCs, we assessed mRNA expression levels of fatty acid synthase ($fasn$), acetyl-coenzyme A carboxylase 1 ($acc1$), carnitine palmitoyltransferase 1a ($cpt1a$), $cpt1b$, monoacylglycerol lipase ($magl$), gpat1, gpat2, gpat3, gpat4, stearoyl-CoA desaturase 1 ($scd1$), scd2, scd3, scd4, lysophosphatidic acid acyltransferase-$\alpha$ ($lpaat$), $lpaat\beta$, $lpaat\delta$, and $lpaat\varepsilon$. Hypoxia increased the mRNA expression levels of gpat1, scd1, $lpaat$, $lpaat\beta$, $lpaat\delta$, and $lpaat\varepsilon$, whereas glucosamine treatment increased only gpat1 mRNA expression (Figure 3a). Immunofluorescence staining results showed a 210% increase in the fluorescence intensity of Gpat1 in the glucosamine and hypoxia-treated mESCs and a 137% increase in the fluorescence intensity of Gpat1 in hypoxia-treated mESCs (Figure 3b). Furthermore, glucosamine-induced Gpat1 expression was inhibited by ST045849 pretreatment (Figure 3c). However, tunicamycin, a N-linked glycosylation inhibitor, did not affect glucosamine-induced Gpat1 expression of mESCs under hypoxia (Supplementary Figure S1). As shown in Figures 3d and e, hypoxia and glucosamine stimulated O-GlcNAcylation and nuclear translocation of Sp1. Nuclear translocation of Sp1 was regulated by the addition of ST045849 and the OGA inhibitor PUGNAc. After 24 h of hypoxia and hypoxia with glucosamine treatments, fluorescence intensity of Sp1 in the PI-stained region increased to 129% and 193%, respectively. However, total fluorescence intensity of Sp1 was not affected by hypoxia and hypoxia treatment (Figure 3f). In addition, pretreatment with the Sp1 inhibitor mithramycin A (1 $\mu$M) suppressed glucosamine-induced Gpat1 expression (Figure 3g). However, the inhibition of SREBP1 activity by fatostatin pretreatment did not affect glucosamine-induced Gpat1 expression (Supplementary Figure S2).

antibody specific for O-GlcNAc. Hypoxia treatment for 24 h slightly increased total O-GlcNAc level, and the maximum increase in O-GlcNAc level was observed in cells treated with 10 $\mu$M of glucosamine and hypoxia (Figure 1d). As shown in Figure 1e, the effect of another O-GlcNAcylation activator GlcNAc was also similar to that of glucosamine. To determine the effect of glucosamine on mESC survival, we examined cell viability after 24 h of hypoxic incubation with various concentrations of the glucosamine (10 mM to 1 $\mu$M). Hypoxia significantly decreased cell viability, but viability was recovered by 10 $\mu$M of glucosamine treatment (Figure 2a). In addition, hypoxia decreased Bcl-2 expression, and increased Bax, cleaved caspase-9, and cleaved caspase-3 expressions, which were reversed by glucosamine treatment (Figure 2b). Live-cell imaging results showed that the size of mESC colonies with glucosamine under hypoxia was significantly larger than that of the hypoxia controls during 24–48 h incubation (Figure 2c). Next, we investigated whether glucosamine-induced O-GlcNAcylation regulated mESC survival under hypoxia. Addition of the OGT inhibitor ST045849 decreased the previous glucosamine-increased cell viability (Figure 2d). Consistent with this result, the glucosamine treatment reduced annexin V-positive and PI-positive mESCs under hypoxia, which was significantly inhibited by ST045849 addition (Figure 2e).
of these results, we suggest that O-GlcNAcylation has a critical role in glucosamine-induced Sp1 nuclear translocation, which is followed by regulation of GPAT1 expression in mESCs under hypoxia.

Role of GPAT1 in mTOR activation and mESC apoptosis under hypoxia. Next, to determine the effect of lipid metabolic enzymes’ metabolites on mESC survival under hypoxia, we performed cell viability assays after mESC pretreatment with palmitic acid, oleic acid, and LPA. As shown in Figure 4a, the survival effect of LPA was stronger than that of other substrates in mESCs under normoxia or hypoxia. Subsequently, we treated mESCs with glucosamine and gpat1-specific siRNA to assess the role of GPAT1 on mESC survival under hypoxia. Silencing of GPAT1 expression decreased Bcl-2 expression, but increased Bax, cleaved caspase-9, and cleaved caspase-3 expressions (Figure 4b). We performed trypan blue exclusion cell viability assays and annexin V/PI FACS analysis to elucidate further the role of GPAT1. The cell viability of gpat1 siRNA with glucosamine pretreatment was similar to that of hypoxia-treated mESCs (Figures 4c and d). In addition, hypoxia and glucosamine-induced GPAT1 did not affect undifferentiation markers Oct3/4 and nanog expressions (Supplementary Figure S3). These results indicate that glucosamine-induced GPAT1 upregulation in hypoxia significantly affects mESC survival. Subsequently, we investigated the detailed signaling pathway by which GPAT1 induces mESC survival under hypoxia. As shown in Figure 5a, glucosamine treatment phosphorylated mTOR, which was blocked by gpat1 siRNA transfection. We confirmed that glucosamine treatment increased Bcl-2 expression, and decreased Bax, cleaved caspase-9.
expressions and cytochrome c release, which were reversed by 10 nM of mTOR inhibitor rapamycin pretreatment (Figures 5b and c). In addition, glucosamine treatment increased [3H]-thymidine incorporation level of mESCs under hypoxia, which was blocked by rapamycin addition (Supplementary Figure S4). Next, we treated LPA to determine the role of GPAT1 metabolite in mESC apoptosis under hypoxia. We examined cell viability after 24 h of hypoxic incubation with various concentrations of LPA (1 μM to 1 nM). The 1 μM and 0.1 μM LPA pretreatments significantly increased the cell viability of mESCs under hypoxia (Figure 5d). In addition, hypoxia and hypoxia with 1 μM of LPA pretreatments increased phosphorylation of mTOR and mTOR substrates (S6K1 and 4EBP1). The LPA-induced phosphorylation of mTOR and mTOR substrates were suppressed by pretreatment with the LPA receptor inhibitor Ptx (Figure 5e). After hypoxia and hypoxia with LPA treatment, the fluorescence intensity of p-mTOR in mESC colonies increased to 187% and 342%, respectively versus hypoxia treatment alone. (d) Cells were pretreated ST045849 (20 μM) for 30 min before treatment of glucosamine (10 μM) for 30 min. Subsequently, cells were exposed to hypoxia for 24 h. Cell viability were measured directly using a Petroff-Hausser cell counting chamber. Error bars are reported as mean ± S.E.M. of three independent experiments with duplex dishes. *P<0.05 versus control, #P<0.05 versus hypoxia treatment alone, and @P<0.05 versus hypoxia with glucosamine. (e) Cells were immunostained with FITC-conjugated annexin V antibody and PI, and analyzed by flow cytometry. Annexin V-negative-PI-negative cells (Q3) were considered viable, annexin V-negative-PI-positive cells (Q1) were considered necrotic, annexin V-positive-PI-negative cells (Q2) were considered late apoptotic, and annexin V positive-PI-negative cells (Q4) were considered early apoptotic. Data are presented as a mean ± S.E.M. of two independent duplex dishes. *P<0.05 versus control, #P<0.05 versus hypoxia treatment alone, and @P<0.05 versus hypoxia with glucosamine.
NF-κB, the activation marker (Supplementary Figure S5). However, NF-κB inhibitor SN-S0 did not affect LPA-induced survival effect on mESCs under hypoxia (Supplementary Figure S6). On the basis of these results, we suggest that LPA activates the mTOR pathway, resulting in mESC survival under hypoxia.

**Role of GPAT1 on mESC survival and skin flap survival.** We performed mouse skin flap surgery to test the protective roles of glucosamine and GPAT1 on transplanted mESC survival. Twelve days after surgery, an extended necrotic area in the central and distal part of the flap appeared in the vehicle, glucosamine, and LPA alone control groups. The necrotic area of the NT siRNA-transfected mESCs alone group was smaller than that of vehicle group. The necrotic region in the skin flap was reduced to a significantly greater extent in NT siRNA-transfected mESCs with either glucosamine or LPA treatment than that in the NT siRNA-transfected mESCs alone group. However, the necrotic area of the gpalt siRNA-transfected mESCs with glucosamine treatment group was larger than that of the NT siRNA-transfected mESCs with glucosamine treatment group (Figure 6b). Histological evaluation, via H&E staining, showed an intact epithelial layer in the NT siRNA-transfected mESCs with glucosamine or LPA treatments, which indicates that mESCs with glucosamine treatment can stimulate skin flap survival under ischemic conditions (Figure 6c). Immunohistochemistry results showed that glucosamine and LPA significantly increased the number of BrdU-positive mESCs in the skin flap. The number of gpalt siRNA-transfected mESCs in the glucosamine treatment group was similar to that in the NT siRNA-transfected mESCs alone group (Figure 6d).

**Discussion**

The results of the present investigation demonstrate the role of GPAT1 expression via augmented O-GlcNAcylation in mESC survival under hypoxia. Although the effect of hypoxia on stem cell survival is not fully elucidated, we observed that increasing the exposure of mESC to hypoxia resulted in duration-dependent apoptosis. Mishra et al. reported that an increase in the Bax/ Bcl-2 ratio is essential for caspase-9-mediated mitochondrial apoptosis under hypoxia. In this study, hypoxia and glucosamine treatments increased O-GlcNAc level, and glucosamine-augmented O-GlcNAcylation suppressed hypoxia-induced mESC apoptosis. In support of our results, there are several reports that glucosamine activates HBP flux and has a protective role via O-GlcNAcylation in other types of cells including cardiomyocytes and retinocytes. Moreover, our previous study established that glucosamine induces OGT expression, which is followed by an increase in O-GlcNAc levels in mESCs. However, a high dose (> 1 mM) of glucosamine did not induce the mESC protective effect. There are several reports showing that a high level of glucosamine-induced HBP activation generates excess ROS, leading to apoptosis. In addition, there are several reports suggesting that O-GlcNAc signaling contributes to undifferentiation and self-renewal. Furthermore, several reports suggest that hypoxia-induced O-GlcNAc signaling regulates metabolic alteration as well as survival responses against noxious stimuli in stem cells. These results indicate the need to clarify the interaction of O-GlcNAc signaling-mediated cell survival with metabolic alteration. Based upon current and past results, we suggest that O-GlcNAcylation is a key factor in maintaining of stem cell populations in vivo.

There are several recent reports on the interaction between lipid metabolic alteration by hypoxia and stem cell regulation. Indeed, several researchers have reported that hypoxia regulates lipid metabolic processes including fatty acid synthesis and β-oxidation. Our present study shows that hypoxia increased levels of metabolic enzymes that contribute to fatty acid and bio-lipid metabolite production and phosphatidic acid signaling. These lipid metabolites have been reported to have the ability to control stem cell functions such as migration, proliferation, and survival. In addition, alteration of lipid metabolic enzyme profiles by hypoxia appears stem cell type-specific. Our previous paper reported that hypoxia predominantly increased FASN in human mesenchymal stem cells (hMSCs), which regulates hMSC proliferation and migration. Ben-David et al. reported that SCD1 inhibition eliminated undifferentiated human ESCs selectively, but our previous study showed that SCD1 inhibition did not affect hMSC proliferation. Taken together, these results indicate a difference in lipid sensitivity between stem cell types. In particular, it is noteworthy that glucosamine up-regulates GPAT1 expression through O-GlcNAcylation, which has an important role in mESC survival under hypoxia. GPAT1 is a lipid metabolic enzyme localized at the mitochondrial outer membrane and is a major form of four GPAT isoforms. GPAT1 metabolizes glycerol-3-phosphate with long chain fatty acyl-CoA to form LPA. Although no reports have demonstrated a role of GPAT1 in stem cells, several investigators have reported that GPAT1 is a factor potentially controlling various cellular processes such as lipid metabolism, mitochondrial dynamics, apoptosis, and proliferation in other cell types. Further investigation into GPAT1’s effect and the detailed mechanism for that effect in stem cells will provide information important for stem cell regulation. As Sp1 is emerging as a potential therapeutic target in metabolic diseases, interest in its effect on metabolic and nutritional regulation is increasing. Furthermore, Sp1 is a transcription factor binding to the human GPAT1 promoter and regulating gene expression. In addition, there are several reports suggesting that a HBP flux-mediated protective effect is induced via O-GlcNAcylation of specific proteins. Moreover, O-GlcNAcylation of Sp1 is important for its subcellular localization, stabilization, and transcriptional regulation. Taken together, these findings indicate that Sp1 regulation by O-GlcNAcylation can be a practical approach to metabolic regulation of stem cell fate.

Furthermore, our results demonstrate that O-GlcNAcylation-mediated GPAT1 expression significantly suppresses hypoxia-induced mESC mitochondrial apoptosis and increases proliferation via mTOR activation, which may suggest that glucosamine-induced resistance against hypoxia is attributed to GPAT1 signaling-mediated mTOR activation. The GPAT1 metabolite LPA has been reported as a potential bioactive lipid molecule that can modulate stem cell function. You et al. reported that LPA activates...
the mTOR pathway via an LPA receptor-mediated ERK activation pathway. In addition, there are reports that mTOR is a nutrient-sensing molecule and can regulate stem cell survival. A previous study reported that AKT/mTOR pathway activation increased the expression of anti-apoptotic proteins Bcl-2 and Bcl-xL, resulting in cell survival and growth. This result suggests that there may be an interaction between GPAT1 signaling-mediated mTOR activation and apoptosis-related protein expression. In this study we demonstrate that glucosamine-induced GPAT1 expression increased mESC survival after transplantation; moreover, it prevented ischemia-induced flap necrosis in vivo in an animal model. The effects of glucosamine and GPAT1 on transplanted stem cell survival demonstrated in this study...
Figure 4  Role of GPAT1 in mESCs apoptosis under hypoxia. (a) Cells were pretreated with palmitic acid (10 μM), oleic acid (10 μM), and LPA (0.1 μM) before hypoxia treatment for 24 h. Cell viability was measured with trypan blue exclusion assay. Error bars are showed as a mean ± S.E.M. of three independent experiments with duplex dishes. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone. (b) Cells were transfected with gpat1 and non-targeting (NT) siRNA for 24 h before glucosamine (10 μM) treatment for 30 min, and then cells were exposed to hypoxia for 24 h. Total lysates were blotted with GPAT1, Bcl-2, Bax, caspase-9, caspase-3, and β-actin. The NT siRNA was used as a negative control. Each blot represented image of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with glucosamine. (c) Cell viability was measured directly by trypan blue exclusion assay using counting chamber. Data are presented as a mean ± S.E.M. of three independent experiments with duplex dishes. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with glucosamine. (d) Viable cells were measured by using annexin V/PI flow cytometry analysis. Annexin V-negative/PI-negative cells (Q3) were considered viable, annexin V-negative/PI-positive cells (Q2) were considered early apoptotic, and annexin V-positive/PI-negative cells (Q4) were considered late apoptotic. Data are presented as a mean ± S.E.M. of two independent duplex dishes. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with glucosamine.

Role of glucosamine-induced O-GlcNAcylation of SP1 in GPAT1 expression. Cells were pretreated with glucosamine (10 μM) for 30 min before hypoxia treatment; and then, cells were exposed to hypoxia for 24 h. (a) Total mRNA from mESCs was reverse-transcribed and qPCR amplified by PCR. The mRNA expression levels were measured by using real-time PCR. Each mRNA expression was normalized by β-actin mRNA expression level. Data are presented as a mean ± S.E.M. of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with glucosamine. (b) Cells were immune-stained with GPAT1 antibody and PI. Fluorescence intensity (ImageJ arbitrary units) of GPAT1 was analyzed by using ImageJ software (developed by Wayne Rasband, National Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/). The result images are representative of three independent experiments. Data are presented as a mean ± S.E.M. of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with glucosamine. Scale bars = 25 μm (magnification × 800). (c) Cells were transfected with ST045849 (20 μM) for 30 min before glucosamine treatment (10 μM) for 30 min, and then cells were exposed to hypoxia for 24 h. GPAT1 protein expression was measured by using western blotting. Each result shown is representative of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with glucosamine. (d) O-GlcNAcylation of Sp1 was measured with an immunoprecipitation assay as described in the Materials and methods section. RL-2, Sp1, and β-actin protein expressions were detected by western blotting. Each result shown is representative of three independent experiments. (e) Cells were transfected with ST045849 (20 μM) or PUGNAc (10 μM) before glucosamine (10 μM) treatment, and then cells were exposed to hypoxia for 24 h. Collected cells were fractionized into non-nuclear and nuclear fractions. Sp1, β-actin, and lamin A/C were detected by western blotting. Each result shown is representative of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with glucosamine. (f) GPAT1 was detected by immune-staining with GPAT1 antibody. Fluorescence intensity of total GPAT1 and GPAT1 within nuclear region were analyzed by using ImageJ software. Error bars are presented as a mean ± S.E.M. of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone. Scale bars = 25 μm (magnification × 800). (g) Cells were pretreated with mithramycin A (1 μM) for 30 min before glucosamine (10 μM) treatment for 30 min. Subsequently, cells were exposed to hypoxia for 24 h. Total protein was extracted, and blotted with GPAT1. Each result shown is representative of three independent experiments.
may have clinical implications for stem cell-based treatments. To our knowledge, this is the first detailed identification of signaling pathways that allow glucosamine-induced O-GlcNAcylaton to control lipid metabolic alteration and provide cytoprotection against hypoxia in stem cells (Figure 5j); thus, suggesting that lipid metabolic regulation via O-GlcNAcylation could be a novel strategy in stem cell therapy. Further investigation into the identification of key metabolic pathways that can regulate stem cell fate and function may hold additional promise for various stem cell applications. In conclusion, our results show that O-GlcNAcylation of SP1-induced GPAT1 expression is critical for mESC survival via mTOR activation under hypoxia.

Materials and Methods

Materials. Cells from a mESC line (ES-E14TG2a) were provided by the American Type Culture Collection (Manassas, VA, USA). Fetal bovine serum was purchased from HyClone (Logan, UT, USA). The Bcl-2, Bax, caspase-3, caspase-9, Sp1, cytochrome c, COX IV, β-tubulin, Oct3/4, nanog, β-actin, and Lamin A/C antibodies were acquired from Santa Cruz Biotechnology (Dallas, TX, USA). The RL-2, Glycerol-3-phosphate acyltransferase-1 (GPAT1), and ALG10 antibodies were obtained from abcam (Cambridge, MA, USA). Mammalian target of rapamycin (mTOR), p-mTOR (Ser 2448), S6K1, p-S6K1 (Thr 389), 4EBP1, and p-4EBP1

Role of GPAT1 on mESCs under hypoxia

HJ Lee et al

Cell Death and Disease
mESC culture. The mESCs were cultured with 15% FBS, 1% antibiotic mixture, 5 ng/ml mouse leukemia inhibitory factor (LIF), and high glucose Dulbecco's essential medium (DMEM, Gibco, Grand Island, NY, USA). The cells were grown on six-well plates or 6 or 95 mm culture dishes in an incubator maintained at 37°C with 5% CO₂. After 48 h of cell culture, cells were washed twice with phosphate buffered solution (PBS) and placed in DMEM-supplemented culture medium with 5% serum replacement, 1% antibiotics, and 5 ng/ml LIF (SR-medium). After cells were incubated for 24 h for mESC synchronization, cells were washed twice with PBS and placed in SR-medium with agents.

Hypoxia treatment. For hypoxia treatment, a modular incubation chamber (Billups-Rothenberg, Del Mar, CA, USA) was used. The hypoxic gas included 2.2% O₂, 5.5% CO₂, and 92.3% N₂ (Billups-Rothenberg, Del Mar, CA, USA). All procedures using animals followed the National Academy of Sciences guidelines. The surgical procedure for flap creation was performed under Institutional Animal Care and Use Committee–approved protocols at Seoul National University (SNU-1505084-B). Mice were housed in a standard animal facility maintained on a 12 h light/dark cycle and within a room temperature range of 20–25°C. Eight-week-old male Institute of Cancer Research mice were anesthetized with 2% isoflurane in oxygen/nitrous oxide mixtures. A previously described skin flap model procedure was performed. Experimental animals were divided into seven groups: vehicle-injected wild-type mice (group 1, n = 6); mESC transplantation mice that received mESC pretreated with either NT siRNA alone (group 2, n = 6) or NT siRNA and 10 μM gpat1 (group 3, n = 6); mice that received mESC pretreated with gpat1 siRNA and 10 μM gpat1 (group 4, n = 6); mice that received 10 μM gpat1 with vehicle (group 5, n = 6); mice that received mESC pretreated with 0.1 μM LPA (group 6, n = 6); and mice that received 0.1 μM LPA with vehicle (group 7, n = 6). After shaving off the hair, a 4 cm × 1 cm skin flap template on the dorsal surface of the mouse was traced by using a surgical marker. The surgical procedure for flap creation was performed under aseptic conditions. A full-thickness skin flap was elevated for 30 min. For treatment, 100 μl of a PBS and matrigel (BD Biosciences, Franklin Lakes, NJ, USA) mixture containing vehicle or mESCs (n = 1 × 10⁴) with either gpat1 siRNA or LPA was injected into the dermis at the center of the skin flap. The flap was then sutured back to its original position by a simple interrupted suturing technique using 3-0 silk non-absorbable sutures (Figure 6a). Transplanted mESCs were pretreated with BrDU (2 μM). All flap images were acquired at the same distance from the subject (30 cm) with a digital camera system (DS50; Nikon, Tokyo, Japan). At post-injection day 12, all mice were killed and 1.5 cm × 0.5 cm tissue samples in the central part of the skin flap were excised and collected (Figure 6a). Collected tissues were embedded in OCT compound (Sakura Finetek, Torrance, CA, USA) and frozen. Embedded samples were sliced (10-μm thick), and underwent hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining. Sliced samples for IHC analysis were immunostained with BrdU and PI. Immunostained cells were visualized by using fluorescence microscopy (Olympus, Tokyo, Japan), and the images were analyzed by using MetaMorph software (Universal Imaging, West Chester, PA, USA). Visual assessment of skin flap necrotic areas was performed by using ImageJ software (developed by Wayne Rasband, National Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/). Dark areas with scabs in a skin flap were considered necrotic. To determine the portion of the skin flap that was necrotic, we used the formula: Necrotic area in skin flap = necrotic area of flap area/total flap x 100.

Western blot analysis. After normoxic or hypoxic incubation, cells were collected by using a cell-collecting scraper. Collected samples were washed twice with ice-cold PBS prior to incubation in RIPA lysis buffer (Thermo Fisher) containing proteinase and phosphatase inhibitor (Thermo Fisher) for 30 min on ice. Next, the lysates were centrifuged for clearance (15 000 r.p.m. at 4°C for 30 min). The protein concentration in the lysate was determined by using a bicinchoninic acid assay kit (Bio-Rad, Hercules, CA, USA). Obtained protein (10 μg) was then loaded in 10% SDS-polyacrylamide gel for electrophoresis and transferred to a polyvinylidene fluoride (PVDF) membrane. The protein-transferred membrane was washed with tris-buffered saline containing a 0.1% Tween-20 (TBST) solution (10 mM Tris-HCl (pH 7.6), 150 mM NaCl, and 0.1% Tween-20) and blocked with 5% skim milk or 5% bovine serum albumin for 15 min. The membranes were then washed with TBST solution for 30 min and incubated with primary antibody (1:1000 dilution) overnight at 4°C. The membranes were washed again and then incubated with HRP-conjugated secondary antibody (1:10 000 dilution) for 6 h at 4°C. The western blotting bands were detected by using enhanced chemiluminescence (Bio-Rad). Densitometric analysis of western blotting bands was quantified by using ImageJ software.

Figure 5 Involvement of mTOR in GPT1-induced mESCs anti-apoptosis under hypoxia. (a) Cells were treated with gpat1 and NT siRNA for 24 h before glosacine (10 μM) for 30 min. Collected samples were lysed, and p-mTOR, GPT1, and β-actin protein expressions were measured by using western blotting. Each result shown is representative of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with gpat1. (b) Cells were treated with rapamycin (10 nM) before glosacine (10 μM) treatment; and then, cells were exposed to hypoxia for 24 h. Total proteins were extracted, and blotted with β-actin, Bax, cleaved caspase-9, and β-actin. Each result shown is representative of three independent experiments. (c) Cells were pretreated with gpat1 siRNA and 10 μM gpat1 before rapamycin (10 nM) for 30 min before hypoxia treatment, and cytokerin c, COX IV, and β-tubulin in the cytosolic and mitochondrial fraction were detected by western blot. (d) Cells were pretreated with various concentrations of LPA (10⁻⁶–10⁻³ M) before hypoxia treatment for 24 h. Cell viability was measured by trypan blue exclusion assay. Error bars are presented as mean ± S.E.M. of three independent duplex dishes. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone. (e) Cells were pretreated with pertussis toxin (100 ng/ml) for 30 min before LPA (0.1 μM) for 30 min. Subsequently, cells were exposed to hypoxia treatment for 24 h. Total proteins were extracted and blotted with β-actin, NF-kB, and p-β-actin. Each result shown is representative of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with LPA. (f) p-mTOR was immunostained with p-mTOR antibody, and counter-stained with PI. Fluorescence images were acquired using an confocal microscopy. Fluorescence intensity of p-mTOR was quantified by using ImageJ software. Data are presented as a mean ± S.E.M. of three independent experiments. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with LPA. (g) Cells were pretreated with rapamycin (10 nM) before LPA (0.1 μM) treatment; and then, cells were exposed to hypoxia for 24 h. Total proteins were extracted, and blotted with BrdU-2, Bax, cleaved caspase-9, cleaved caspase-3, and β-actin. Each result shown is representative of three independent experiments. (h) Cell viability was measured by using cell counter. Data are presented as a mean ± S.E.M. of three independent duplex dishes. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with LPA. (i) Viable cells were measured by using annexin V/PI flow cytometry analysis. Annexin V-negative/PI-negative cells (Q3) were considered viable, annexin V-negative/PI-positive cells (Q1) were considered necrotic, annexin V-positive/PI-negative cells (Q2) were considered late apoptotic, and annexin V-positive/PI-negative cells (Q4) were considered early apoptotic. Data are presented as a mean ± S.E.M. of two independent duplex dishes. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with LPA. *P < 0.05 versus control, †P < 0.05 versus hypoxia treatment alone, and ‡P < 0.05 versus hypoxia with LPA. The proposed model for signaling pathways involved in glosacine-induced mESCs survival under hypoxia [j]
Nuclear and Non-nuclear fraction preparation. Harvested samples were suspended in buffer A solution (137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, 2.5 mM EDTA, 1 mM dithiothreitol, 0.1 mM PMSF, and 10 mg/ml leupeptin (pH 7.5)). Suspended cells were homogenized mechanically by using a 23-gauge needle and then incubated for 10 min. Cell lysates were centrifugated at 8000 r.p.m. for 5 min at 4 °C. Supernatant, as the non-nuclear fraction, was collected. The obtained pellet, as the nuclear fraction, was then lysed with RIPA lysis buffer containing protease and phosphatase inhibitor.

Isolation of mitochondria. Samples were extracted using the commercial mitochondria isolation kit for cultured cells (Thermo Fisher) according to the manufacturer’s manual. Collected cells were suspended in Reagent A, and then

Figure 6  Role of GPAT1 in mESCs survival in the mouse skin flap model. Mouse skin flap surgery with BrdU-harborred mESCs transplantation was performed as described in Materials and methods section. (a) NT siRNA-transfected cells are injected in the center region (I) of the flap. At post-injection day 12, all tissue samples (S) including injection site in are excised and collected. (b) Representative gross images of skin flap were obtained at day 12 after flap surgery. Necrotic area in skin flap was analyzed by using ImageJ software. Error bars indicate a mean ± S.E.M. n = 5. *P < 0.05 versus vehicle group, #P < 0.05 versus mESCs group, and ^P < 0.05 versus mESCs with glucosamine group. (c) Tissue samples were stained with hematoxylin and eosin. Histological images shown in result are representative. Scale bars, 100 μm (magnification, ×40 and ×100). (d) BrdU was immunostained with BrdU specific antibody and PI for nuclear counting, and samples were visualized by using confocal microscopy. BrdU and PI-stained cells were analyzed by using MetaMorph software. Scale bars, 200 μm (magnification, ×100 and ×200). *P < 0.05 versus mESCs group, and #P < 0.05 versus mESCs with glucosamine group. C, crust; Ep, epidermis; D, dermis; GT, granulated tissue; ND, not detected.
incubated for 2 min on ice. Reagent B was added to samples, and then incubated for 5 min. Subsequently, Reagent C was added to samples. Cell lysates were centrifuged at 3000 g for 15 min. Supernatant, as cytosol fraction, was collected. The obtained pellet, as mitochondrial fraction, was then lysed with 2% CHAPS in Tris-buffered saline (25 mM Tris, 0.15 M NaCl; pH 7.2).

Immunoprecipitation. Collected cells were lysed with non-denaturing lysis buffer (20 mM Tris-HCl pH 8.0, 136 mM NaCl, 1% NP40, and 2 mM EDTA) including proteasean and phosphatase inhibitors. Immunoprecipitation lysates were incubated with an appropriate primary antibody overnight. Subsequently, Protein A/G-PLUS-Agarose immunoprecipitation reagents (Santa Cruz Biotechnology) were added to lysates for 4 h. Samples were washed twice with non-denaturing lysis buffer. Similar amounts of samples were loaded in 10% SDS-polyacrylamide gel for electrophoresis and then transferred to a PVDF membrane. Blotting bands were visualized with an enhanced chemiluminescence solution (Bio-Rad).

mRNA isolation and reverse transcription polymerase chain reaction. The mESCs RNA was extracted by using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA). Extracted RNA (1 μg) was reverse-transcribed with a Maxime RT premix kit (INNORN Biotechnology, Sungnam, Korea). The cDNA was amplified with the sense and antisense primers of gpat1 and β-actin. Real-Time PCR. Expressions of the fasn, acot1, acpt1, cpt2, magl, gpat1, gpat2, gpat3, gpat4, scd1, scd2, scd3, scd4, lpaat, and β-actin genes were detected by using a Rotor-Gene 6000 real-time thermal cycling system (Corbett Research, Mortlake, NSW, Australia) with a QuantiMix SYBR kit (Philie Korea Technology, Daejeon, Korea), mRNA primers, and 1 μg of the cDNA sample. Data were analyzed by using the manufacturer's software (Corbett Research). Melting curve analysis was used to confirm the identity and specificity of the PCR products. Normalization was performed by using β-actin as the endogenous control. Primer sequences used in experiments are described in Supplementary Table S1.

Small interfering RNA transfection. Prior to transplantation or hypoxia treatment, siRNAs specific for gpat1 or NT siRNA as a negative control were transfected to mESCs for 24 h with HiPerfect transfection reagent (Qiagen) according to the manufacturer’s description. Each transfected siRNA’s concentration was 25 nM. The siRNA sequences are described in Supplementary Table S2.

Trypan blue exclusion cell viability assay. Cell-cultured medium was collected and the cells were washed twice with ice-cold PBS. Washed cells were suspended with a 0.05% Trypsin and 0.5 mM EDTA solution. The collected medium was added to the cell suspension solution, including detached cells, and the mixture was treated with soybean trypsin inhibitor (0.05 mg/ml) to quench trypsin activity. Trypan blue (0.4%; Sigma-Aldrich) was added to the cell suspension to stain the dead cells. Stained cells and all cells were counted by using a Petroff-Hausser counting chamber (Hausser Scientific, Horns, PA, USA). Cell viability was determined by using the following formula. Cell viability = [1 – (number of trypan blue-stained cells/number of total cells)] × 100.

Annexin V/PI Fluorescence-activated cell sorter analysis. Annexin V and PI staining was performed by using Annexin V and PI staining kit (BD Bioscience) according to the manufacturer’s instruction. Briefly, cell-cultured medium was collected. The mESCs were detached with a 0.05% Trypsin and 0.5 mM EDTA solution and the collected medium was added to the cell suspension, followed by the addition of soybean trypsin inhibitor (0.05 mg/ml). Next, 1 × 10⁵ cells were resuspended in 1× binding buffer, immunostained with 5 μl of FITC Annexin V and 5 μl of PI, and incubated at 25 °C for 15 min in the dark. Analysis was performed by using flow cytometry (Beckman Coulter, Fullerton, CA, USA). From each sample, 5 × 10⁵ cells were obtained and analyzed by using CXP software (Beckman Coulter).

Intracellular reactive oxygen species (ROS) detection. Intracellular ROS was detected by using CM-H2DCF-DA (DCF-DA, Life Technologies, Gaithersburg, MD, USA), a H₂O₂-sensitive fluorophore. Cells were detached with a 0.05% Trypsin and 0.5 mM EDTA solution, and 5 × 10⁵ cells were resuspended in 10 μl DCF-DA in PBS and incubated at 25 °C for 30 min in the dark. In order to quantify the intracellular ROS levels, the cells were rinsed twice with ice-cold PBS followed by resuspension in ice-cold PBS. A 150 μl aliquot of cell suspension was loaded into a 96-well plate and fluorescence was detected by using a lumimometer (Victor3, Perkin-Elmer, Waltham, MA, USA) with excitation and emission wavelengths of 485 and 535 nm, respectively.

Immunofluorescence staining. Cells were fixed with 80% acetone in PBS for 10 min, followed by washing with PBS. Sequentially, cells were incubated with 5% normal goat serum to inhibit non-specific binding of antibody, and then incubated with primary antibody (1:100 dilution) overnight at 4 °C. Next, the cells were incubated for 1 h with Alexa flour 488-conjugated anti-rabbit and anti-mouse IgG secondary antibody (1:100 dilution, Life Technologies) and PI in PBS. Images were acquired via a Fluoview 300 fluorescence microscope (Olympus). For quantification of protein expression, we calculated the corrected total cell fluorescence (CTCF, ImageJ arbitrary unit) by using ImageJ software. The equation used to determine CTCF was CTCF = Integrated density — (Area of selected cell × Mean fluorescence of background readings). Three independent experiments were performed, and the CTCF of 15 colonies (5 colonies per experiment) were obtained.

Live-cell imaging. After glucosamine or LPA treatment, the culture dish was placed in a temperature and CO₂ control chamber (Toki, Tokyo, Japan). Normoxic or hypoxic gas was supplied for 48 h. Differential interference contrast images were acquired over those 48 h at 10 min intervals by using an Olympus IX61-ZDC zero-drift microscope and a Cascade 512B camera (Roper Scientific, Tucson, AZ, USA). A constant threshold of each image was maintained. Determination of the mESC colony area was performed by using ImageJ software.

[³H]-Thymidine incorporation. After treatment, the mESCs were treated with 1 μCi of [methyl-³H]-thymidine (Amersham Biosciences, Piscataway, NJ, USA), and incubated for 1 h at 37 °C. The mESCs were washed with cold PBS, fixed in 10% trichloroacetic acid for 1 h, and then washed with cold PBS. The acid-insoluble substance was lysed with 2N NaOH for 4 h. The level of [³H]-thymidine incorporation with DNA was detected using a liquid scintillation counter. Data were normalized from absolute counts to controls.

Statistical analysis. All experimental data are summarized as a mean ± standard error. Differences among experimental groups were tested by using ANOVA. To compare some treatment group means with either control or hypoxia treatment means, the Bonferroni-Dunn test was performed. A test result with a P-value <0.05 was considered significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This research was supported by National R&D Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2013M3A9B4076520), and BK21 PLUS Program for Creative Veterinary Science Research.

Author contributions
LHJ: conception and design, collection and/or assembly, analysis and interpretation of data, manuscript writing; JYH: data analysis and interpretation; LKH and YS: methodology; KS: statistical consulting; HJ: data analysis and interpretation; KM: manuscript writing; JY: writing; YS: writing. Theus MH, Wei L, Cui L, Francis K, Hu X, Keogh C et al.

Role of Gpat1 on mESCs under hypoxia
HJ Lee et al
6. Song H, Cha MJ, Song BW, Kim K, Chang W, Lim S et al. Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Stem Cells 2010; 28: 555–563.

7. Csete M. Oxygen in the cultivation of stem cells. Ann N Y Acad Sci 2005; 1049: 1–8.

8. Holbrook NJ, Ikeyama S. Age-related decline in cellular response to oxidative stress: links to growth factor signaling pathways with common defects. Biochem Pharmacol 2002; 64: 999–1005.

9. Kumar S, Ashraf M. The molecular basis of pluripotency in mouse embryonic stem cells. Mol Biol Cell 2013; 24: 1332–1341.

10. Tessa L, Tettet MA. Perturbant stem cell energy metabolism: an update. EMBO J 2015; 34: 138–153.

11. Lee HJ, Ryu JM, Jung YH, Oh SY, Lee SJ, Han HJ. Novel pathway for hypoxia-induced proliferation and migration in human mesenchymal stem cells: involvement of HIF-1α, FASLN, and mTORC1. Stem Cells 2015; 33: 2182–2185.

12. Wells L, Vosseller K, Hart GW. Glycylolation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001; 291: 2376–2378.

13. Hart GW, Houssley MP, Slawson C. Cycling of O-linked N-acetylglucosamine on nucleocytoplasmic proteins. Nature 2007; 446: 1017–1022.

14. Love DC, Honavar JA. The hexosamine signaling pathway: deciphering the “O-glucosamine” code. SCITEK 2005; 2005: re13.

15. Guillaumond F, Loca J, Olavres E, Lavaud MN, Vidal N, Berthezene P et al. Strengthened glycolysis under hypoxia supports tumor spheroids and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2013; 110: 3919–3924.

16. Dorkenwald B, Roseman S, Moses FE, Ludwing J, Mayeda M. The biosynthesis of hyaluronic acid by group II Streptococcus. II. Origin of the N-acetylglucosamine moiety. J Biol Chem 1955; 218: 583–591.

17. Marshall S, Bascot V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1991; 266: 4706–4712.

18. Ghosh S, Blumenthal HJ, Davidson E, Roseman S. Glucosamine metabolism. V Enzymatic and molecular characterization of a novel N-acetylglucosaminyltransferase isozyme in Streptococcus mutans. J Biol Chem 1990; 265: 12657–12673.

19. Shafi R, Iyer SP, Ellies LG, O’Donnell N, Marek KW, Chui D et al. Elevated O-GlcNAc levels activate epigenetically repressed genes and delay mouse ESC differentiation without affecting naive to primed cell transition. Stem Cells 2014; 32: 2605–2615.

20. Jiang H, Kim TW, Yoon S, Choi SY, Kang TW, Kim SY et al. O-GlcNAc regulates pluripotency and reprogramming by directly acting on core components of the pluripotency network. Cell Stem Cell 2012; 11: 62–74.

21. Song C, Song C, Tong F. Autophagy induction is a survival response against oxidative stress in bone marrow-derived mesenchymal stromal cells. Cytotherapy 2014; 16: 1361–1370.

22. Gutierrez-Urquiza A, Areshchadra M, Bragado P, Aguirre-Ghizon J, Poeras A, P3R-mediates cell survival in response to oxidative stress via induction of antioxidant genes: effect on the p70S6K pathway. J Biol Chem 2012; 287: 2632–2642.

23. Ferrer CM, Lynch TP, Sod V, Falcone JN, Schwab LP, Peacock DL et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 and p70S6K pathways. Mol Cell 2014; 54: 820–831.

24. Kuramochi M, Tamura Y, Tada M, Umeno S, Inoue M et al. The role of O-GlcNAcylation in the regulation of maintenance of self-renewal in mouse embryonic stem cells. Stem Cells Dev 2013; 22: 2975–2989.

25. Zafir A, Readpower R, Low BW, McCracken J, Afd A, Alvarez A et al. Protein O-GlcNAcylation is a novel cytoprotective isotype in cardiac myocytes. Stem Cells 2013; 31: 765–775.

26. Liu J, Pang Y, Chang T, Bountela P, Chatham JC, Marchase RB. Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. J Mol Cell Cardiol 2006; 40: 303–312.

27. Hardiville S, Hart GW. Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAc. Cell Metab 2014; 20: 208–213.

28. Ruan HB, Singh JP, Li MD, Wu J, Yang X. Cracking the O-GlcNAc code in metabolism. Trends Endocrinol Metab 2013; 24: 301–309.

29. Koc, Caracceo A, Weiss D, Ara F, Au A, Awan DE et al. A PML-PPAR-α pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 2012; 18: 1360–1368.

30. Holmes CD, Park S, Terzic A. Lipid metabolism governs the stem cell engine. Cell Metab 2013; 17: 153–155.

31. O’Shea KS. Self-renewal vs. differentiation of mouse embryonic stem cells. Biol Reprod 2004; 71: 1755–1765.

32. Chamber J. The molecular basis of pluripotency in mouse embryonic stem cells. Cloning Stem Cells 2004; 6: 386–391.

33. Murre CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008; 132: 661–680.

34. Lee KB, Choi J, Cho SB, Chung YJ, Moon ES, Kim NS et al. Topical embryonic stem cell extraction from hair follicles. Clin Orthop Res 2011; 29: 1554–1562.

35. Hodgson DM, Behar A, Zingman LV, Kane GC, Perez-Terzic C, Aleskeev AE et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol 2004; 287: H471–H479.

36. Laffamme EA, Chen KY, Naumov AV, Mukhevi V, Fugate JA, Dupras SK et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of isolated rat hearts. Nat Biotechnol 2007; 25: 1015–1024.

37. Koay EJ, Athanasiou KA. Hypoxic chondrogenic differentiation of human embryonic stem cells enhances cartilage protein synthesis and biomechanical functionality. Osteoarthritis Cartilage 2010; 18: 1456–1462.

38. Khan WS, Adesida AB, Hardingham TE. Hypoxic conditions increase hyaluronan-inducible transcription factor 2α and enhance chondrogenesis in stem cells from the infrapatellar fat pad of osteoarthritis patients. Arthritis Res Ther 2007; 9: R55.

39. AmatoNni PM, Behm MJ, Metzner DW. Mucosal B cell deficiency in IgA−/− mice abrogates the development of allergic lung inflammation. J Immunol 2005; 175: 1277–1285.

40. Pouwels MJA, Jacobs JR, Span PN, Lutterman JA, Smith P, Tack CJ. Short-term glycylolation infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab 2001; 86: 2099–2103.
64. Champattanachai V, Marchase RB, Chatham JC. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am J Physiol Cell Physiol 2007; 292: C178–C187.

65. Goldberg HJ, Scholey J, Fantus IG. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes 2000; 49: 863–871.

66. Kudlow JE. Post-translational modification by O-GlcNAc: another way to change protein function. J Cell Biochem 2006; 98: 1062–1075.

67. Dottori M, Leung J, Turner AM, Puey A. Lysophosphatidic acid inhibits neuronal differentiation of neural stem/progenitor cells derived from human embryonic stem cells. Stem Cells 2006; 26: 1146–1154.

68. Ortlepp C, Steudel C, Heiderich C, Koch S, Jacobl A, Ryser M et al. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. Exp Hematol 2013; 41: 444–461.e4.

69. Costa M, Sourris K, Lim SM, Yu QC, Hirist CE, Parkinson HC et al. Derivation of endothelial cells from human embryonic stem cells in fully defined medium enables identification of lysophosphatidic acid and platelet activating factor as regulators of eNOS localization. Stem Cell Res 2013; 10: 103–117.

70. Liu X, Hou J, Shi L, Chen J, Sang J, Hu S et al. Lysophosphatidic acid protects mesenchymal stem cells against ischemia-induced apoptosis in vivo. Stem Cells Dev 2009; 18: 947–954.

71. Yoo JS, Frey JW, Hornberger TA. Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid. Plos One 2012; 7: e47258.

72. Montagari SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006; 66: 4715–4724.

73. Kumar D, Shankar S, Srivastava RK, Rottmann induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett 2014; 343: 179–189.

74. Zhou J, Wulfsbier J, Zhang H, Gu P, Yang Y, Deng J et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007; 104: 16158–16163.

75. Marinov M, Zgiavas A, Pardo OE, Tan LT, Ohtlon T, Mauri FA et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2005; 11: 1277–1287.

76. Morimoto A, Tomita S, Imanishi M, Shiog O, Kihira Y, Izawa-Ishizawa Y et al. Overexpressed HIF-2α in endothelial cells promotes vascularization and improves random pattern skin flap survival. Plast Reconstr Surg Glob Open 2014; 2: e132.

77. Basu G, Downey H, Guo S, Israel A, Amsar A, Hargrave B et al. Prevention of distal flap necrosis in a rat random skin flap model by gene electro transfer delivering VEGF(165) plasmid. J Gene Med 2014; 16: 55–65.

78. de Carvalho EN, Ferreira LM, de Carvalho NA, Alba LE, Liebano RE. Viability of a random pattern dorsal skin flap, in diabetic rats. Acta Cir Bras 2005; 20: 225–228.